International position paper on febuxostat

Research output: Contribution to journal › Review article › Contributed › peer-review

Contributors

  • Tim L. Jansen - , Medical Centre Leeuwarden (Author)
  • Pascal Richette - , Université Paris Cité (Author)
  • Fernando Perez-Ruiz - , Hospital de Cruces (Author)
  • Anne Kathrin Tausche - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)
  • Philip André Guerne - , University of Geneva (Author)
  • Leonardo Punzi - , University of Padua (Author)
  • Burkhard Leeb - , State Hospital Stockerau (Author)
  • Victoria Barskova - , Russian Academy of Medical Sciences (Author)
  • Till Uhlig - , Diakonhjemmet Hospital (Author)
  • José Pimentão - , Santa Cruz Hospital (Author)
  • Irena Zimmermann-Górska - , University of Medical Sciences Poznan (Author)
  • Eliseo Pascual - , Hospital General Universitario de Alicante (Author)
  • Thomas Bardin - , Université Paris Cité (Author)
  • Michael Doherty - , University of Nottingham (Author)

Abstract

This position paper aims to clarify the presumed place of febuxostat in the management of gout patients. Since this novel xanthine oxidase inhibitor is now available, an international group of gout experts decided to formulate an international consensus statement. This statement presents the place for this new xanthine oxidase inhibitor in the treatment of gout which may contribute to optimize treatment of gout patients in Europe and worldwide.

Details

Original languageEnglish
Pages (from-to)835-840
Number of pages6
JournalClinical rheumatology
Volume29
Issue number8
Publication statusPublished - Aug 2010
Peer-reviewedYes

External IDs

PubMed 20401506

Keywords

ASJC Scopus subject areas

Keywords

  • Allopurinol, Febuxostat, Gout, Urate-lowering therapy, Uricosuric, Xanthine-oxidase inhibitor